Dear All
I'm trying to evaluate a transit model approach in an attempt to better
describe early drug concentrations following intravenous injection (1 minute
and 10 minute infusions) of a sedative-hypnotic drug. However, every
minimisation attempt is terminated due to rounding errors (E=134).
Ann
Try ADVAN6 or ADVAN8 or ADVAN13 .
Also, TOL=3 is too small. Increase it to 6-7 or even 9, and also change
to NSIG=3 SIGL=9 ($EST step, as recommended in the guide).
Also, at least initially, I would remove ETAs from the third compartment
and from one of the parameters (Q2 or V2) of the seco
Ann
I think your model is starting to be over-parameterised: 4 compartments plus
lag plus transit (have you plotted the individual alag estimates as they have
fairly big omegas?) I think if you cannot describe the data well with a 4 comp
linear model, and are seeing differences in PK with diffe
Expert Modeler position at Novartis Pharmaceuticals (Basel, Switzerland)
The company: a global healthcare leader, Novartis has one of the most
exciting product pipelines in the industry today. A pipeline of innovative
products brought to life by diverse, talented, performance-driven people.
A
I'd like to get the group's opinion on something. I have a pharmacodynamic
model and the baseline was shown to be a covariate on one of the model
parameters. I was hoping to get general thoughts on the use of the baseline as
a covariate. Is there a preference for using the observed baseline v
Hi Pete,
In this setting I generally try to first model the baseline response and
perhaps pursue alternative structural model forms. For example, I may
consider a multiplicative relationship rather than an additive relationship
between baseline and placebo/drug effects. However, if the distribut
Xiao,
Try running a SIMONLY simulation first. If you are using an additive or
additive + constant CV error model, simulation will sometimes generate
negative or very tiny DV values. If this is the case, it will cause
problems with fitting the model to the simulated data.
Luann
Xiao Hu wrote
Hi Peter,
I assume from the question that the baseline is the baseline of your
modeled PD measure, not of some other value (like the baseline weight),
and that you model the actual PD measure, not change from the baseline.
Then
- it would be more logical to use the model-predicted baseline;
-
Dear Dr. Bonate,
Could you kindly elaborate on the structural model that is being used to
characterize your PD system? In my limited experience, I have seen the
behavior that you describe under 2 circumstances:
a) Simple inhibitory Emax PD model with a baseline: Here patients with a
higher baselin
Hi Pete,
I think the standard model most of us would use is baseline as a parameter
in the model, and like other parameters it would have a variability between
subjects. What you describe sounds like a covariance between the baseline
parameter and some other parameter. We are used to include such
10 matches
Mail list logo